DEA Continues to Block MMJ Marijuana Drug Development for Neurological Disorder
-
Eli Crane Defeats Jonathan Nez in Tight Arizona Congressional Race
-
David Walliams Identified as Celebrity in Sexual Misconduct Allegations After Legal Bid
-
Sherilyn Smith Encourages Women to Embrace Scars as Symbols of Resilience
-
Korea's Severe Asthma Patients Blocked from Biologics by Restrictive Reimbursement Rules
-
Belgium Signs Contract for 20 Rheinmetall Skyranger Air Defence Systems
-
Shanghai Science and Technology Museum Signs Pacts With London and Ottawa Institutions at CIIE
-
BioTech Breakthrough Acknowledges Champions Oncology Innovation with the "Contract Research and Development Innovation Award"
-
New Gold IRA Investing Guide Explains How to Buy Gold in an IRA for American Consumers
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 10
-
Fulcrum Metals PLC Announces Fulcrum to Increase Shareholding in Loyalist
-
Spectrocell Strengthens Product Discovery and Customer Engagement with Bioz Badges
-
3D Induced Polarization Survey Identifies a Large Drill Target at East Goldfield
-
Apex Extends Trinity Zone in West Step-out Drilling With 2.52% REO Over 223.3 m and 2.49% REO Over 123.3 m at Rift
-
KIFFIK Biomedical Recognized as Top Biomarker Access Technology 2026 by Life Sciences Review
-
Zomedica Announces "Third Friday at Four" Webinar on November 20, 2026: The People Behind Zomedica - Seven Guiding Principles in Action, and Q3 Financial Results
-
Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule
-
Geek+ Unveils 24/7 Warehouse Autonomy Plan to Advance Self-Optimizing, Around-the-Clock Operation
-
Gamma Resources Announces Planned Radon Flux Baseline Survey at Mesa Arc Uranium Project in New Mexico, Provides Update on Project Timelines
-
China Explores a New Pathway for Medical AI: Bridging R&D Innovation and Clinical Adoption
-
Critical Elements' 10,000-Meter Summer Drill Program at Rose West Continues to Deliver Positive Results
-
Aztec Drills 70.1 Meters of 0.80 g/t AuEq (0.49 g/t Au and 16.85 g/t Ag) from Surface in TR26-54 at the Tombstone Project, Arizona
-
Silicon Publishing Launches Prism, Bringing AI-Assisted Automation to Database Publishing
-
Zeb Nickel Commences Diamond Drilling at the Zeb Nickel Project
-
Aston Bay Announces Pre-Feasibility Study Results and Maiden Mineral Reserve for the Storm Copper Project, Nunavut
-
Electrovaya to Participate in Upcoming Investor Conferences
-
Moderna to Present at Upcoming Conference in November 2026
-
INEO Invited to 15th Annual ROTH Technology Conference in New York
-
Odyssey Behavioral Healthcare Launches Virtual Intensive Outpatient Mental Health Treatment for Adults
-
Nextech3D.ai to Report Fiscal Second Quarter 2027 Financial Results and Host Investor Webinar on November 19, 2026 at 4:30 PM ET
-
Adcore Reports Third Quarter 2026 Results: Gross Margin Rises to 64%, Operating Loss Halved, Cash Up to $4.3 Million as Restructuring Takes Hold
-
Sterling Metals Announces Fully Allocated Private Placement of Units, Flow-Through Shares and Charity Flow-Through Units
-
Wash100 Award, GovCon Industry's Highest Honor, Opens Nominations for 2027 Season
-
Greene Concepts Highlights Groundwater Resources and Commercial Opportunities
-
SNZweig Forms AEC Industry Advisory Council
-
Allstar Health Brands Confirms MLS NEXT Expansion Bid to Anchor a Permanent Training Structure and a Professional Pathway
-
Securitas Healthcare Introduces a New Era of RTLS Built for the Future of Healthcare Operations
-
Horizon Aircraft Completes Preliminary Design Review of Cavorite X7 Hybrid eVTOL
-
Cardiff Lexington To Report Third Quarter 2026 Financial Results and Host Conference Call on Monday, November 16, 2026
-
ATWEC Technologies, Inc. (OTCID:ATWT) Reports Third Quarter 2026 Revenue of $12.46 Million, Up 37% Year-over-Year
-
ByNext Joins the Bilt Neighborhood: Reaching More Customers by Integrating Its Technology with Bilt Neighborhood OS
-
Your Patients Are Asking AI About You. AimwellBio Lets Every Physician See the Answer, Free.
-
Peraso to Showcase DUNE 60 GHz Wireless Platform at Africa Tech Festival 2026
-
Four Nines Gold Intersects 67 Metres at 1.78 g/t Gold, Reinforing Emerging Gold Corridor at Hayden Hill
-
Medical Care Technologies Inc. (OTCID:MDCE) Subsidiaries to Manage $20 Million in Private Collectibles Assets
-
Opportunistic Trader ETF(WZRD) to Delist and Liquidate
-
LiveOne (Nasdaq: LVO) Releases Preliminary H1 Fiscal 2027 Results: $37.3 Million in Revenue and Record Audio Adjusted EBITDA* of $7.8 Million, Up 619% Year-Over-Year
-
Critics and Listeners Agree: Eylsia Nicolas' "The Wedding Song" Nominated for GlacerFM's Best Pop Song 2026; Second Consecutive Listener's Choice Nomination Follows Widespread Critical Recognition and Growing Global Audience
-
GoodData.AI Launches the Agentic Serving Plane, a New Category of Enterprise Data Infrastructure for AI Agents
-
Guard Home Warranty Launches Claims 2.0: A Real US-Based Person in 16 Seconds, Claims Reimbursed Instantly
-
Envision Pharma Group appoints Leigh Anne Siino as Senior Vice President of Commercial, Two Labs and Riparian
DEA Continues to Block MMJ Marijuana Drug Development for Neurological Disorder
MMJ Submits FDA Investigational New Drug Application for Cannabis-Derived Drug
MMJ International Holdings has taken a significant step forward by submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its novel cannabis-derived medication. This significant move anticipates FDA approval to initiate comprehensive clinical trials, focusing on the treatment of chorea associated with Huntington's disease (HD). This step is a testament to MMJ's dedication to harnessing the therapeutic benefits of cannabis in advancing medical science.
In addition to this application, MMJ has secured an Orphan Drug designation, which highlights its commitment to addressing the critical needs of Huntington's disease patients. This designation facilitates a faster clinical trial process, focusing on validating the efficacy of their investigational drug.
Despite facing regulatory challenges, MMJ remains steadfast in its mission to develop impactful cannabinoid-derived medicines. The upcoming Phase 2 clinical trial for MMJ-002 aims to showcase its potential to significantly mitigate the debilitating effects of Huntington's chorea, with the goal of enhancing clinical outcomes and improving patient quality of life.
MMJ's commitment extends beyond U.S. borders, as it navigates through DEA-imposed barriers to marijuana drug development. The company has strategically expanded its drug development operations internationally, circumventing domestic regulatory hurdles. This international approach is due to ongoing legal disputes involving the Department of Justice (DOJ) and the DEA, which are accused of contravening the presidential marijuana research act.
With a robust approach to drug discovery and development, supported by a strong intellectual property portfolio and manufacturing expertise, MMJ International Holdings continues to spearhead innovations in the medical cannabis landscape, pushing the boundaries of what is possible in cannabinoid medicine.
MMJ is represented by Attorney Megan Sheehan of Rhode Island.
CONTACT:
Madison Hisey
mhisey@mmjih.com
203-231-8583
SOURCE: MMJ International Holdings
D.Sawyer--AMWN